← Leaderboards
Marcela Romero-Reyes
University Of Maryland Baltimore
$628,530
Attributed
$1,422,090
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $620.3K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,422,090 · 2
By mechanism
R01$1,190,340 · 1
R03$231,750 · 1
Top collaborators
- Simon Akerman2 shared
- Daniela Salvemini2 shared
Most similar at University Of Maryland Baltimore
Same institution · by research overlap
- Daniela Salvemini$13,229,020
- Michael S Gold$16,352,215
- Asaf Keller$13,995,714
- Radi Masri$4,603,782
- Simon Akerman$1,348,526
Others in their field
Other Emerging Leaders on “Prevent”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Leonard Freedman · Leidos Biomedical Research, Inc.$141,293,697
- Kimberly Smith · Ppd Development Lp$115,671,664
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$112,282,390
- Beth Baseler · Leidos Biomedical Research, Inc.$100,071,064
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$76,895,673
Research focus
PreventTrigeminal NucleiMolecularPathway InteractionsResponseSpinalImmunohistochemistryMediatingNociceptionPain ModelReceptorReportingSafetySignal PathwayChronicAttenuatedInsightBehavioralAgonistDisabilityPainPainful NeuropathyProductionTrigeminal Pain
Grant awards (4)
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$570,062
R01 · FY2025 · NS
Molecular basis for functional S1PR1 antagonists in the treatment of comorbid migraine and temporomandibular disorders$620,278
R01 · FY2024 · NS
Targeting trigeminal neuropathic pain with selective A3AR agonists$115,875
R03 · FY2018 · DE · contact PI
Targeting trigeminal neuropathic pain with selective A3AR agonists$115,875
R03 · FY2017 · DE · contact PI